BridgeMD
New treatment option for Hepato Cellular Carcinoma
Official title PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
ClinicalTrials.gov ID: NCT07393074
What this study is testing
- What it's testing
- Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally. Despite advances in the treatment of hepatitis B and C, metabolic diseases, and addiction, HCC incidence continues to rise.
- Time commitment: about 5 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Group A:
- Over 18 years of age
- Affiliated with a social security system
- Sufficient command of the French language to hold a conversation and read
- Signature of an informed consent form
You likely can't join if
- Personal history of cancer in the broad sense (including HCC prior to inclusion in the study)
- Pregnant or breastfeeding women
- Adults subject to legal protection measures (guardianship, curatorship)
- Contraindications to trans-parietal liver biopsy: clinical or radiological ascites, coagulation disorders, curative anticoagulation that cannot be...
- Persons deprived of their liberty by judicial or administrative decision
- Wearers of electronic implants (pacemakers, implantable cardioverter defibrillators, cochlear implants, brain implants, etc.)
See the full eligibility criteria
- Group A:
- Over 18 years of age
- Affiliated with a social security system
- Sufficient command of the French language to hold a conversation and read
- Signature of an informed consent form
- Compensated cirrhosis classified as CHILD-Pugh A with clinical indication for liver biopsy (either for the etiological diagnosis or confirmation of cirrhosis, or for the etiological diagnosis of liver damage)
- Liver biopsy scheduled as part of routine care for a diagnosis of cirrhosis without HCC Group B:
- Over 18 years of age
- Affiliated with a social security system
- Sufficient command of the French language to hold a conversation and read
- Signature of an informed consent form
- Compensated cirrhosis classified as CHILD-Pugh A with clinical indication for liver biopsy (either for the etiological diagnosis of cirrhosis or its confirmation; or for the etiological diagnosis of liver damage)
- Liver biopsy scheduled as part of routine care for the diagnosis of suspected HCC (based on standard imaging criteria)
- Personal history of cancer in the broad sense (including HCC prior to inclusion in the study)
- Pregnant or breastfeeding women
- Adults subject to legal protection measures (guardianship, curatorship)
- Contraindications to trans-parietal liver biopsy: clinical or radiological ascites, coagulation disorders, curative anticoagulation that cannot be suspended, dilation of the bile ducts
- Persons deprived of their liberty by judicial or administrative decision
- Wearers of electronic implants (pacemakers, implantable cardioverter defibrillators, cochlear implants, brain implants, etc.)
- Psychotic disorders
- Degenerative neurological disorders (Parkinson's disease and related disorders, dementia, Korsakoff's syndrome, etc.)
- Antiarrhythmic treatment:
- Class Ia: Disopyramide and Quinidine
- Class Ic: Flecainide and Propafenone
- Neuroleptic psychotropic treatment affecting the ANS (haloperidol, chlorpromazine, olanzapine, clozapine, quetiapine), tricyclic antidepressants (e.g., amitriptyline, amoxapine, clomipramine, etc.)
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.